РЕВОЛЮЦИЯ, КОТОРУЮ МЫ ПОЧТИ ПРОСПАЛИ

Расшифровка генома человека и появление относительно простых методов секвенирования сделало возможным расшифровку генетической природы значительного числа заболеваний, в том числе и в кардиологии. Каналопатии, кардиомиопатии, семейные формы гиперлипидемии, легочная артериальная гипертония — эти заболевания за рубежом являются показанием для углубленного генетического исследования. Статья посвящена описанию показаний для рутинного применения секвенирования нового поколения. 

1. Heart Failure Society of A. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 2010, 16(6): 475-539.

2. Semsarian C, Ingles J, Wilde AAM. Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. European Heart Journal 2015, 36(21): 1290-6.

3. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart rhythm: the official journal of the Heart Rhythm Society 2013, 10(12): 1932-63.

4. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. The Canadian journal of cardiology 2011, 27(2): 232-45.

5. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart rhythm : the official journal of the Heart Rhythm Society 2011, 8(8): 1308-39.

6. National guidelines for the definition of risk and prevention of sudden cardiac death. Clinical practice 2012(4):6-75.Russian (Национальные рекомендации по определению риска и профилактике внезапной сердечной смерти. Клиническая практика 2012 (4): 6-75).

7. Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart rhythm : the official journal of the Heart Rhythm Society 2009, 6(3): 341-8.

8. Kim JJ, Nemec J, Li Q, et al. Synchronous Systolic Subcellular Ca2+-Elevations Underlie Ventricular Arrhythmia in Drug-Induced Long QT Type 2. Circulation Arrhythmia and electrophysiology 2015:CIRCEP.114.002214.

9. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 2015, 36(14): 847-55.

10. Protonotarios A, Anastasakis A, Panagiotakos DB, et al. Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2015:euv061.

11. Groeneweg JA, Bhonsale A, James CA, et al. Clinical Presentation, Long-Term FollowUp, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circulation Cardiovascular genetics 2015, 8(3): 437-46.

12. Bezzina CR, Lahrouchi N, Priori SG. Genetics of Sudden Cardiac Death. Circ Res 2015, 116(12): 1919-36.

13. Corrado D, Zorzi A. Arrhythmogenic right ventricular cardiomyopathy and sports activity. Eur Heart J 2015:ehv183.

14. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension, vol. 30; 2009.

15. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias, vol. 32; 2011. 16. Giudicessi JR, Ackerman MJ. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res 2013, 161(1): 1-14.